Data

A Phase II signal-seeking trial targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification - IGNITE

Health Data Australia Contributor Records
Au-Yeung, George ; Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58107/JZJ9-RF14&rft.title=A Phase II signal-seeking trial targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification - IGNITE&rft.identifier=http://doi.org/10.58107/JZJ9-RF14&rft.publisher=Australia New Zealand Gynaecological Oncology Group&rft.description=Dataset contains: - Data for 80 patients with recurrent high grade serous ovarian carcinoma with Cyclin E1 (CCNE1) overexpression - Approximate time period of data collection 2020-2026 - Clinical benefit rate at 18 weeks post-intervention commencement - Toxicity - Progression free survival, overall survival - Best overall response (BOR) - Duration of response (DoR)&rft.creator=Au-Yeung, George &rft.creator=Australia New Zealand Gynaecological Oncology Group (ANZGOG) &rft.date=2027&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12619001185156&rft_subject=Cancer therapy (excl. chemotherapy and radiation therapy)&rft.type=dataset&rft.language=English Access the data

Full description

Dataset contains: - Data for 80 patients with recurrent high grade serous ovarian carcinoma with Cyclin E1 (CCNE1) overexpression - Approximate time period of data collection 2020-2026 - Clinical benefit rate at 18 weeks post-intervention commencement - Toxicity - Progression free survival, overall survival - Best overall response (BOR) - Duration of response (DoR)

Notes

HeSANDA 1.0.0

Available: 2027

Issued: 2027

This dataset is part of a larger collection

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
AstraZeneca

ROR : https://ror.org/04wwrrg31

Identifiers